Oyster Point Pharma, Inc. OYST
11.17 +11.17
Day range unavailable
52-week range unavailable
- Market cap
- 299.85M
- Revenue (ttm)
- 19.58M
- Shares out
- 26.84M
- Forward P/E
- -3.50
- Beta
- 1.28
- Analysts
- Hold
- Price target
- 15.00 (+34.3%)
- Earnings date
- Feb 23, 2023
YTD -6.48 (-36.71%)
Key statistics
- Enterprise value
- 325.77M
- PEG ratio
- 0.00
- Price / sales
- 15.31
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -68.80%
- Free cash flow
- -97.05M
- Total cash
- 68.80M
- Total debt
- 94.72M
- Return on equity
- -306.38%
- Short % of float
- 2.04%
- 50-day average
- 11.07
- 200-day average
- 7.32
Analyst view
Consensus: hold
Hold
Price target (mean) 15.00 +34.3% upside
Now 11.17
- Target (low)
- 11.00
- Target (mean)
- 15.00
- Target (high)
- 22.00
Ratings (-1m) 5 3 buy · 2 hold · 0 sell
- Strong buy0
- Buy3
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 23, 2023
Expected Feb 23, 2023. Consensus EPS estimate -1.26.
Financials — quick view
OYST Revenue — quarterly 5.59M
OYST Net income — quarterly -36.75M
OYST EPS — quarterly -1.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2023 | Dec 1, 2022 | -1.19 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -1.52 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -1.64 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -1.75 | — | — | — |
| Feb 24, 2022 | Dec 1, 2021 | -1.39 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -1.16 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2022 | Chardan Capital | down | Buy | Neutral |
| Nov 8, 2022 | Piper Sandler | down | Overweight | Neutral |
| Aug 11, 2022 | Chardan Capital | init | — | Buy |
| Jul 18, 2022 | HC Wainwright & Co. | init | — | Buy |
| Nov 9, 2021 | JP Morgan | down | Overweight | Neutral |
| Nov 25, 2019 | JP Morgan | init | — | Overweight |
About Oyster Point Pharma, Inc.
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- oysterpointrx.com
News
Earnings Scheduled For November 10, 2022 
Dow Surges 400 Points; Crude Oil Down 1% 
Dow Jumps Over 200 Points; Verve Therapeutics Shares Plummet - 10 Short Squeeze Candidates That May Soar: Minerva Neurosciences, FaZe, Getty Images And More
- This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
- Stocks That Hit 52-Week Lows On Wednesday
Stocks That Hit 52-Week Lows On Tuesday 
Stocks That Hit 52-Week Lows On Wednesday 
Earnings Scheduled For May 5, 2022 - Stocks That Hit 52-Week Lows On Friday
Your note
Sign in to keep a note on OYST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ATIEH MICHAEL G | Director | Stock Award(Grant) | Jun 5, 2022 | 26,734 |
| BEHBAHANI ALI | Director | Stock Award(Grant) | Jun 5, 2022 | 13,639 |
| ELIADES GEORGE CHRISTOPHER | Director | Stock Award(Grant) | Jun 5, 2022 | 28,624 |
| LOCHNER DANIEL J. | Chief Financial Officer | Stock Award(Grant) | Jan 6, 2022 | 77,721 |
| MURRAY MARK ANTHONY | Director | Stock Award(Grant) | Jun 5, 2022 | 122,086 |
| OZAWA CLARE | Director | Stock Award(Grant) | Jun 5, 2022 | 3,672,260 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 22.07% | 5,925,287 | 66.19M | Sep 29, 2022 |
| Invus Financial Advisors, LLC | 10.31% | 2,768,586 | 30.93M | Sep 29, 2022 |
| RTW Investments LP | 7.62% | 2,044,312 | 22.83M | Sep 29, 2022 |
| Point72 Asset Management, L.P. | 6.73% | 1,805,387 | 20.17M | Sep 29, 2022 |
| Paradigm Biocapital Advisors LP | 6.14% | 1,648,316 | 18.41M | Sep 29, 2022 |
| Kohlberg Kravis Roberts & Co. L.P. | 3.87% | 1,039,622 | 11.61M | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.86% | 232,158 | 2.59M | Sep 29, 2022 |
| Fidelity Strategic Advisors Small-Mid Cap Fund | 0.76% | 203,167 | 2.27M | Sep 29, 2022 |
| John Hancock Fds II-New Opportunities Fund | 0.66% | 177,931 | 1.99M | Nov 29, 2022 |
| Vanguard Extended Market Index Fund | 0.64% | 171,624 | 1.92M | Sep 29, 2022 |
| BlackRock Advantage Small Cap Core Fund | 0.44% | 118,721 | 1.33M | Aug 30, 2022 |
| iShares NASDAQ Biotechnology ETF | 0.39% | 103,996 | 1.16M | Nov 29, 2022 |